



Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room – WO66-0609
Silver Spring, MD 20993-0002

Mr. Matt Clausen
Regulatory Affairs
Medline Industries, Incorporated
One Medline Place
Mundelein, Illinois 60060

OCT - 2 2009

Re: K090568

Trade/Device Name: Medline Powder-Free Nitrile Examination Glove with Aloe
(Green) – Tested for use with Chemotherapy Drugs

Regulation Number: 21CFR 880.6250

Regulation Name: Patient Examination Glove

Regulatory Class: I

Product Code: LZC, LZA

Dated: September 22, 2009

Received: September 23, 2009

Dear Mr. Clausen:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,



Susan Runner, D.D.S., M.A.

Acting Director

Division of Anesthesiology, General Hospital,

Infection Control and Dental Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): K090568

Device Name:

Medline Powder-Free Nitrile Examination Glove with Aloe (Green) – Tested for use with Chemotherapy Drugs

Indications For Use:

The Medline Powder-Free Nitrile Examination Glove with Aloe (tested for use with chemotherapy drugs) is a disposable device intended for medical purposes that is worn on the examiner's hand to prevent contamination between patient and examiner.

The tested chemotherapy drugs and their breakthrough detection times are as follows:

Chemotherapy Drug	Average BDT
5-Fluorouracil	>240 min.
Etoposide (Toposar)	>240 min.
Cyclophosphamide (Cytoxan)	>240 min.
Carmustine	19.31 min.
Thiotepa	26.88 min.
Paclitaxel (Taxol)	>240 min.
Doxorubicin Hydrochloride	>240 min.
Dacarbazine (DTIC)	>240 min.
Cisplatin	>240 min.
Ifosfamide (Ifex)	>240 min.
Mitoxantrone	>240 min.
Vincristine Sulfate	>240 min.

WARNING: Do not use with Carmustine and Thio-Tepa.


(Division Sign-Off)

Division of Anesthesiology, General Hospital
Infection Control, Dental Devices

510(k) Number: K090568

Prescription Use _____
(Part 21 CFR 801 Subpart D)

OR

Over-the-Counter Use X _____
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)